Iylon Precision Oncology shared a post on LinkedIn about a recent article by Nelson Dusetti et al, published in Cancer Treatment Reviews:
“Precision Oncology in Pancreatic Ductal Adenocarcinoma (PDAC).
In this paper ‘Medical management of pancreatic cancer: from personalization to broadening treatment strategies’, Dr. Nelson Dusetti, Dr. Pascal Hammal and team summarize the current status of Precision Oncology in Pancreatic Ductal adenocarcinoma (PDAC).
Pancreatic ductal adenocarcinoma is a very aggressive cancer, because each patient’s tumor behaves differently. New approaches aim to personalize treatment by using tumor gene analysis, lab-grown tumor models, and simple blood tests to help doctors choose the best therapies and monitor how the cancer changes over time. Although some targeted treatments only work for a small number of patients, they offer new options and are being tested in clinical trials. Combining these tools could make pancreatic cancer treatment more precise, effective, and better tailored to each patient.
At Iylon Precision Oncology, we harness genetic insights to provide personalized, evidence-based recommendations, helping guide the right medicine, for the right patient, at the right dose, at the right time, and aimed at the right target.”
Title: Medical management of pancreatic cancer: from personalization to broadening treatment strategies
Authors: Nelson Dusetti, Jean Baptiste Bachet, Brice Chanez, Cindy Neuzillet, Louis de Mestier, Nicolas Williet, Nicolas Frauhoffer, Remy Nicolle, Alice Boilève, Anthony Turpin, Raphaël Rodriguez, Jérôme Cros, Juan Iovanna, Pascal Hammel
Read the Full Article on Cancer Treatment Reviews
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared this post, adding:
“This raises an important point about how we currently rethink treatment strategies in complex diseases.
Moving from isolated personalization to more integrated frameworks is clearly becoming a central challenge.
In this article, we raise these questions and aim to contribute to the ongoing discussion.
We are grateful to Iylon Oncology for highlighting this work and for helping bring these discussions to a broader audience.”
More posts featuring Nelson Dusetti.